The analyst consensus price target for Plexus has increased by $4.40 to $159.00. This reflects upward revisions in revenue growth expectations and ongoing confidence in management’s execution, even as some firms have issued cautious outlooks recently.

Analyst Commentary

Recent analyst updates on Plexus offer a nuanced perspective on the company’s outlook, reflecting both optimism about its trajectory and caution around market factors.

Bullish Takeaways

• Bullish analysts continue to raise their price targets in response to better-than-expected sales and earnings. This supports a view of ongoing strength in Plexus' core business.
• Management’s execution on strategic initiatives is drawing consistent praise and contributes to sustained confidence in the company's ability to navigate dynamic market conditions.
• Recent management meetings have reinforced expectations for growth. Analysts cite fundamental expansion and a robust finish to the fiscal year as key positives.
• Despite shares trading near the upper end of their historical valuation range, upward revisions to targets reflect belief in the company’s longer-term growth trajectory.

Bearish Takeaways

• Some bearish analysts are scaling back fiscal year 2026 and 2027 estimates due to uncertain macroeconomic conditions and cautious management commentary.
• Downgrades to Neutral from Buy highlight concerns that, while current results are solid, future challenges from a softer environment could limit upside.
• Analysts maintaining Hold recommendations are citing valuation concerns, noting that Plexus shares are already priced at the higher end of their historical range.

What's in the News

• Plexus completed the repurchase of 160,364 shares, representing 0.59% of shares outstanding, for $21.5 million under the buyback announced on May 14, 2025 (Key Developments).
• Plexus initiated fiscal first quarter 2026 revenue guidance, with a target revenue range of $1.050 billion to $1.090 billion and GAAP diluted EPS of $1.40 to $1.55. This guidance includes $0.26 in stock-based compensation expense (Key Developments).
• No shares were repurchased in the tranche from May 14 to June 28, 2025, under the previously announced buyback program (Key Developments).

Valuation Changes

• Consensus Analyst Price Target has increased to $159.00 from $154.60, reflecting higher expected fair value.
• Discount Rate has risen slightly to 8.37 percent from 8.28 percent, which suggests marginally higher perceived risk or capital costs.
• Revenue Growth assumptions have moved up significantly to 7.53 percent from 6.14 percent, which indicates improved expectations for future sales expansion.
• Net Profit Margin is now projected at 4.22 percent, a modest increase from 4.20 percent. This points to slightly better profitability forecasts.
• Future P/E has edged lower to 24.86x from 25.25x, implying a subtle shift in relative earnings valuation expectations.